Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Inhibition of metastasis by inhibition of tumor-derived CCL5.

Authors: Stormes, Kerry A  Lemken, Charles A  Lepre, James V  Marinucci, Michelle N  Kurt, Robert A 
Citation: Stormes KA, etal., Breast Cancer Res Treat. 2005 Jan;89(2):209-12. doi: 10.1007/s10549-004-5328-3.
Pubmed: (View Article at PubMed) PMID:15692764
DOI: Full-text: DOI:10.1007/s10549-004-5328-3

To determine whether tumor-derived CCL5 contributes to the metastatic potential of murine mammary carcinoma, we used the 4T1 tumor which spontaneously metastasizes and constitutively produces CCL5. Mice bearing 4T1 that expressed less CCL5 had significantly fewer lung and liver metastasis. The decrease in tumor-derived CCL5 also correlated with decreased cathepsin L, MMP-2, MMP-3, MMP-10 and MMP-17 gene expression. Thus, inhibition of tumor-derived CCL5 can impact the metastatic capability of 4T1 and may do so by modulating protease expression.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 14995455
Created: 2019-10-24
Species: All species
Last Modified: 2019-10-24
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.